Thompson Siegel & Walmsley LLC Has $11.51 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Thompson Siegel & Walmsley LLC decreased its stake in QuidelOrtho Co. (NASDAQ:QDEL) by 5.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 252,455 shares of the company’s stock after selling 15,347 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in QuidelOrtho were worth $11,512,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of QuidelOrtho during the third quarter valued at approximately $25,000. Fifth Third Bancorp lifted its position in shares of QuidelOrtho by 907.3% during the 2nd quarter. Fifth Third Bancorp now owns 826 shares of the company’s stock worth $27,000 after buying an additional 744 shares during the period. GAMMA Investing LLC grew its position in QuidelOrtho by 27.0% in the second quarter. GAMMA Investing LLC now owns 1,778 shares of the company’s stock valued at $59,000 after acquiring an additional 378 shares during the period. Innealta Capital LLC acquired a new position in QuidelOrtho during the second quarter worth $102,000. Finally, Quest Partners LLC boosted its stake in shares of QuidelOrtho by 17,095.0% in the 2nd quarter. Quest Partners LLC now owns 3,439 shares of the company’s stock valued at $114,000 after purchasing an additional 3,419 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at QuidelOrtho

In related news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of QuidelOrtho stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $35.31, for a total transaction of $291,667,061.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.00% of the stock is owned by company insiders.

QuidelOrtho Stock Up 1.1 %

QDEL stock opened at $37.89 on Friday. The business has a 50-day moving average of $41.62 and a 200-day moving average of $40.37. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $75.86. The stock has a market capitalization of $2.55 billion, a P/E ratio of -1.34 and a beta of 0.12. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Thursday, November 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.55. The business had revenue of $727.00 million during the quarter, compared to the consensus estimate of $642.16 million. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 earnings per share. On average, sell-side analysts anticipate that QuidelOrtho Co. will post 1.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QDEL has been the subject of a number of research reports. William Blair reissued a “market perform” rating on shares of QuidelOrtho in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price objective on shares of QuidelOrtho in a research report on Friday, August 16th. Craig Hallum raised shares of QuidelOrtho from a “hold” rating to a “buy” rating and raised their target price for the company from $40.00 to $57.00 in a research note on Thursday, September 5th. Finally, UBS Group initiated coverage on shares of QuidelOrtho in a research report on Thursday, September 19th. They issued a “neutral” rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, QuidelOrtho has an average rating of “Hold” and an average price target of $58.83.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.